Holen Sie sich die Stockscreener-App
27.07
0.11%
-0.03
Schlusskurs vom Vortag:
$27.10
Offen:
$27.39
24-Stunden-Volumen:
1.03M
Relative Volume:
1.19
Marktkapitalisierung:
$2.56B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-115.88M
KGV:
-17.50
EPS:
-1.5468
Netto-Cashflow:
$-104.72M
1W Leistung:
+6.62%
1M Leistung:
-1.17%
6M Leistung:
+29.27%
1J Leistung:
+54.69%
1-Tages-Spanne:
$26.62
$29.00
1-Wochen-Bereich:
$25.17
$29.14
52-Wochen-Spanne:
$14.90
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Firmenname
Edgewise Therapeutics Inc
Sektor
Branche
Telefon
720-262-7002
Adresse
1715 38TH ST, BOULDER
Vergleichen Sie EWTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
27.07 | 2.56B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-22 | Eingeleitet | Stifel | Hold |
| 2024-11-22 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2022-08-25 | Herabstufung | Goldman | Neutral → Sell |
| 2022-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-28 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
Edgewise Therapeutics (EWTX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Shares Up 5.9%Here's Why - MarketBeat
10,316 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Acquired by AlphaCentric Advisors LLC - MarketBeat
Should You Invest in Edgewise Therapeutics (EWTX)? - Insider Monkey
What is Edgewise Therapeutics Inc (EWTX) Stock Return on Shareholders’ Capital? - SETE News
Strong Buy Stocks: Udemy, D-Wave Quantum, and Edgewise Therapeutics - PUNE.NEWS
How To Trade (EWTX) - Stock Traders Daily
JPMorgan lifts Edgewise Therapeutics target to $45 - MSN
JPMorgan lifts Edgewise Therapeutics target to $45 By Investing.com - Investing.com UK
Edgewise placed on ‘Positive Catalyst Watch’ at JPMorgan - TipRanks
abrdn plc Sells 78,602 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Alan J. Russell Sells 1,200 Shares - MarketBeat
Insider Selling: Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CEO Sells 8,636 Shares of Stock - MarketBeat
Edgewise Therapeutics chief business officer sells $300,300 in stock - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 7.1% Following Insider Selling - MarketBeat
April 17th Options Now Available For Edgewise Therapeutics (EWTX) - Nasdaq
What was Edgewise Therapeutics Inc (EWTX)’s performance in the last session? - US Post News
Edgewise Therapeutics chief scientific officer sells $276,776 in stock - MSN
Edgewise Therapeutics CEO Kevin Koch sells $287,315 in stock - MSN
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Edgewise Therapeutics' SWOT analysis: novel therapies drive stock potential - MSN
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CEO Kevin Koch Sells 8,636 Shares of Stock - Armenian Reporter
Edgewise Therapeutics CEO Kevin Koch sells $287,315 in stock By Investing.com - Investing.com Australia
Edgewise Therapeutics chief business officer sells $300,300 in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics chief scientific officer sells $276,776 in stock By Investing.com - Investing.com Nigeria
Edgewise Therapeutics Executives Sell Shares - TradingView
An In-Depth Look at Edgewise Therapeutics Inc’s (EWTX) Stock Performance - The News Heater
Can you now get a good deal on Edgewise Therapeutics Inc’s shares? - US Post News
When (EWTX) Moves Investors should Listen - Stock Traders Daily
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap UpStill a Buy? - MarketBeat
Ratios Uncovered: Breaking Down Edgewise Therapeutics Inc (EWTX)’s Trailing Twelve Months Metrics - The Dwinnex
Check out these key findings about Edgewise Therapeutics Inc (EWTX) - SETE News
Edgewise Therapeutics' SWOT analysis: novel therapies drive stock potential By Investing.com - Investing.com South Africa
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CMO Joanne M. Donovan Sells 25,000 Shares - MarketBeat
Finanzdaten der Edgewise Therapeutics Inc-Aktie (EWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Edgewise Therapeutics Inc-Aktie (EWTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
Feb 06 '25 |
Option Exercise |
0.18 |
1,200 |
216 |
16,063 |
| Russell Alan J | Chief Scientific Officer |
Feb 05 '25 |
Sale |
30.02 |
8,015 |
240,623 |
14,863 |
| Russell Alan J | Chief Scientific Officer |
Feb 06 '25 |
Sale |
30.13 |
1,200 |
36,153 |
14,863 |
| KOCH KEVIN | President and CEO |
Feb 06 '25 |
Option Exercise |
13.11 |
900 |
11,799 |
15,378 |
| KOCH KEVIN | President and CEO |
Feb 05 '25 |
Option Exercise |
0.18 |
8,636 |
1,554 |
23,114 |
| KOCH KEVIN | President and CEO |
Feb 05 '25 |
Sale |
30.03 |
8,636 |
259,298 |
14,478 |
| KOCH KEVIN | President and CEO |
Feb 06 '25 |
Sale |
31.13 |
900 |
28,018 |
14,478 |
| Derakhshan Behrad | Chief Business Officer |
Feb 05 '25 |
Option Exercise |
1.93 |
10,000 |
19,300 |
26,837 |
| Derakhshan Behrad | Chief Business Officer |
Feb 05 '25 |
Sale |
30.03 |
10,000 |
300,300 |
16,837 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):